VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Must have given written informed consent (signed   │ Must have given written informed consent (signed   │     100 │
│ and dated) and any authorizations required by      │ and dated) and any authorizations required by      │         │
│ local law                                          │ local law                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ 18 to 75 years old (inclusive)                     │ 18 to 75 years old (inclusive)                     │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Male or female with a diagnosis of PBC, by at      │ Male or female with a diagnosis of PBC, by at      │     100 │
│ least two of the following criteria                │ least two of the following criteria                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of AP above ULN for at least six months    │ History of AP above ULN for at least six months    │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Positive Anti-Mitochondrial Antibodies (AMA)       │ Positive Anti-Mitochondrial Antibodies (AMA)       │     100 │
│ titers (\>1/40 on immunofluorescence or M2         │ titers (>1/40 on immunofluorescence or M2 positive │         │
│ positive by enzyme linked immunosorbent assay      │ by enzyme linked immunosorbent assay (ELISA) or    │         │
│ (ELISA) or positive PBC-specific antinuclear       │ positive PBC-specific antinuclear antibodies       │         │
│ antibodies                                         │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Documented liver biopsy result consistent with PBC │ Documented liver biopsy result consistent with PBC │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ On a stable and recommended dose of UDCA for the   │ On a stable and recommended dose of UDCA for the   │     100 │
│ past twelve months                                 │ past twelve months                                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ AP ≥ 1.67 × ULN                                    │ AP ≥ 1.67 × ULN                                    │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ For females of reproductive potential, use of at   │ For females of reproductive potential, use of at   │     100 │
│ least one barrier contraceptive and a second       │ least one barrier contraceptive and a second       │         │
│ effective birth control method during the study    │ effective birth control method during the study    │         │
│ and for at least two weeks after the last dose.    │ and for at least two weeks after the last dose.    │         │
│ For male subjects, use of appropriate              │ For male subjects, use of appropriate              │         │
│ contraception (e.g., condoms), so their female     │ contraception (e.g., condoms), so their female     │         │
│ partners of reproductive potential do not become   │ partners of reproductive potential do not become   │         │
│ pregnant during the study and for at least two     │ pregnant during the study and for at least two     │         │
│ weeks after the last dose                          │ weeks after the last dose                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ A medical condition, other than PBC, that in the   │ A medical condition, other than PBC, that in the   │     100 │
│ investigator's opinion would preclude full         │ investigator's opinion would preclude full         │         │
│ participation in the study or confound its results │ participation in the study or confound its results │         │
│ (e.g., cancer on active treatment)                 │ (e.g., cancer on active treatment)                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Auto-immune hepatitis                              │ Auto-immune hepatitis                              │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Primary sclerosing cholangitis                     │ Primary sclerosing cholangitis                     │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Known history of alpha-1-Antitrypsin deficiency    │ Known history of alpha-1-Antitrypsin deficiency    │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Known history of chronic viral hepatitis           │ Known history of chronic viral hepatitis           │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Creatine kinase above ULN                          │ Creatine kinase above ULN                          │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Serum creatinine above ULN                         │ Serum creatinine above ULN                         │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ For females, pregnancy or breast-feeding           │ For females, pregnancy or breast-feeding           │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Use of colchicine, methotrexate, azathioprine, or  │ Use of colchicine, methotrexate, azathioprine, or  │     100 │
│ systemic steroids in the two months preceding      │ systemic steroids in the two months preceding      │         │
│ screening                                          │ screening                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Current use of fibrates, including fenofibrates,   │ Current use of fibrates, including fenofibrates,   │     100 │
│ or simvastatin                                     │ or simvastatin                                     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Use of an experimental treatment for PBC           │ Use of an experimental treatment for PBC           │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Use of experimental or unapproved                  │ Use of experimental or unapproved                  │     100 │
│ immunosuppressant                                  │ immunosuppressant                                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Any other condition(s) that would compromise the   │ Any other condition(s) that would compromise the   │     100 │
│ safety of the subject or compromise the quality of │ safety of the subject or compromise the quality of │         │
│ the clinical study, as judged by the Investigator  │ the clinical study, as judged by the Investigator  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ AST or ALT \> 3 × ULN                              │ AST or ALT > 3 × ULN                               │      98 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Total bilirubin \> 2 × ULN                         │ Total bilirubin > 2 × ULN                          │      98 │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤═══════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria         │   Score │
╞═══════════════════════════════════╪═══════════════════════╪═════════╡
│ Must have minimum age of 18 Years │ Auto-immune hepatitis │      37 │
├───────────────────────────────────┼───────────────────────┼─────────┤
│ Must have maximum age of 75 Years │ Auto-immune hepatitis │      37 │
╘═══════════════════════════════════╧═══════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 98
Average Levenshtein Ratio of individual lines: 95.0
OverAll Ratio: 96.5
